trending Market Intelligence /marketintelligence/en/news-insights/trending/9Of_gnyacNADbka9kwzdsA2 content esgSubNav
In This List

Bod Australia gets medicinal cannabis import license

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


Bod Australia gets medicinal cannabis import license

Health products distributor Bod Australia Ltd has been granted an import license for medicinal cannabis products by the New South Wales Department of Health and the Therapeutic Goods Administration, the company said Dec. 4.

The license allows Bod to store and supply medicinal cannabis.

The company said it will now seek permission from the Office of Drug Control, or ODC, to import a range of cannabis products from overseas producers and raw materials from its exclusive partner, Linnea SA. Linnea is a Switzerland-based maker of medicinal cannabis extracts, botanical and pharmaceutical ingredients for use in the pharmaceutical, nutraceutical and cosmetic sectors.

Products containing the plant will be available to authorized prescribers and will be used for the company's clinical trial programs once Bod secures an approval from the ODC.

The move marks a key step for Bod in establishing medical cannabis operations in Australia and improving revenues from the sale of therapeutic goods and extracts. The company said phase 1 of its clinical trial, which aims to test the safety, tolerability and pharmacokinetics of the Linnea phytocomplex cannabis extract, is expected to start in 2018.